Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 14:2018:5389820.
doi: 10.1155/2018/5389820. eCollection 2018.

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

Lumir Kunovsky  1   2 , Pavla Tesarikova  3 , Zdenek Kala  2 , Radek Kroupa  1 , Petr Kysela  2 , Jiri Dolina  1 , Jan Trna  1   3
Affiliations
Review

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

Lumir Kunovsky et al. Can J Gastroenterol Hepatol. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies with increasing incidence. The poor prognosis is due to the aggressive nature of the tumor, late detection, and the resistance to chemotherapy and radiotherapy. A radical surgery procedure is the only treatment that has been shown to improve the 5-year survival rate to 20-25%. However, the majority of patients (80-85%) are diagnosed with locally advanced or metastatic disease and just 15-20% patients are diagnosed in an early stage allowing them to undergo the potentially curative surgical resection. The early detection of PDAC without the use of invasive methods is challenging and discovery of a cost-effective biomarker with high specificity and sensitivity could significantly improve the treatment and survival in these patients. In this review, we summarize current and newly examined biomarkers in early PDAC detection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Characteristics required for biomarkers of pancreatic cancer.
See this image and copyright information in PMC

References

    1. Humphris J. L., Chang D. K., Johns A. L., et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology. 2012;23(7):1713–1722. doi: 10.1093/annonc/mdr561.mdr561 - DOI - PMC - PubMed
    1. Yako Y. Y., Kruger D., Smith M., Brand M. Cytokines as biomarkers of pancreatic ductal adenocarcinoma: A systematic review. PLoS ONE. 2016;11(5) - PMC - PubMed
    1. Wang J., Raimondo M., Guha S., et al. Circulating microRNAs in pancreatic juice as candidate biomarkers of pancreatic cancer. Journal of Cancer. 2014;5(8):696–705. doi: 10.7150/jca.10094. - DOI - PMC - PubMed
    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(1):7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Yu I. S., Cheung W. Y. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Canadian Journal of Gastroenterology and Hepatology. 2018;2018:10. doi: 10.1155/2018/1863535.1863535 - DOI - PMC - PubMed

MeSH terms

Substances